Antonina Levashenko, Head of the International Best Practices Analysis Department at the Gaidar Institute, in her comments to Vedomosti, assessed the interest of users in innovative drugs for the treatment of obesity and type 2 diabetes — semaglutide and tirzepatide.
“In January 2025, users searched for semaglutide drugs 415,800 times, which is 30% more than a year earlier. This indicates a consistently high and growing interest in this group of drugs,” the expert noted, citing Yandex data.
According to the Association of Quality Assessment Organizations, the effectiveness of modern drugs allows to reduce the number of hospitalizations and disability cases, increases the ability to work, and therefore will reduce the RF budget expenditures by up to 20 billion rubles per year.